Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Non-Current Assets (2021 - 2026)

Invivyd's (IVVD) quarterly Non-Current Assets came in at $36.8 million in Q2 2026, up 23.16% on a YoY basis from $29.9 million in Q2 2025, and up 25.0% quarter-over-quarter from $29.4 million in Q4 2025.

Analysis

Invivyd (IVVD) Non-Current Assets (2021 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Non-Current Assets for 6 consecutive years, with $36.8 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Assets rose 23.16% year-over-year to $36.8 million; the trailing twelve-month figure through Jun 2026 stood at $125.4 million (up 28.74% YoY), and the FY2025 full-year result was $29.4 million, up 2.02% from the prior year.
  • Non-Current Assets advanced to $36.8 million in Q2 2026 per IVVD's latest filing, from $29.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $36.8 million in Q2 2026 and bottomed at $2.0 million in Q1 2022.
  • Historically, Non-Current Assets has averaged $14.0 million across 5 years, with a median of $5.9 million in 2023.
  • The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 48.47% in 2022, then surged 588.74% in 2025.
  • Over 5 years, Non-Current Assets stood at $6.2 million in 2022, then tumbled by 31.2% to $4.3 million in 2023, then soared by 570.56% to $28.8 million in 2024, then grew by 2.02% to $29.4 million in 2025, then gained by 25.0% to $36.8 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $36.8 million, $29.4 million, and $29.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 1.96 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 938.60 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 24.78 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 468.65 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn 36.77 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 36.77 Mn
Dec 31, 2025 29.42 Mn
Sep 30, 2025 29.39 Mn
Jun 30, 2025 29.86 Mn
Mar 31, 2025 27.92 Mn
Dec 31, 2024 28.83 Mn
Sep 30, 2024 10.82 Mn
Jun 30, 2024 4.34 Mn
Mar 31, 2024 5.59 Mn
Dec 31, 2023 4.30 Mn
Sep 30, 2023 4.81 Mn
Jun 30, 2023 5.43 Mn
Mar 31, 2023 5.94 Mn
Dec 31, 2022 6.25 Mn
Sep 30, 2022 3.15 Mn
Jun 30, 2022 3.25 Mn
Mar 31, 2022 1.97 Mn
Dec 31, 2021 3.38 Mn
Sep 30, 2021 6.12 Mn
Jun 30, 2021 1.93 Mn